Jvion’s success is based on a profound understanding of the real needs of their partners, which drives the implementation of interoperable, seamless solutions straightforwardly into the clinical workflow.
ATLANTA (PRWEB) September 08, 2020
Jvion, a leader in clinical AI, has continued its momentum in 2020 with new solutions dedicated to addressing COVID-19, supporting the financial recovery of healthcare providers, and enabling payers to predict and mitigate unforeseen member risks.
- The COVID Community Vulnerability Map is a public tool that identifies communities at increased risk for severe illness, hospitalizations and deaths during a COVID-19 outbreak. It also highlights the socioeconomic and environmental risk factors in each US Census block. The map has been viewed over 2 million times and used by various federal agencies as well as medical student groups to guide proactive outreach efforts in vulnerable communities.
- The map was followed by the launch of Patient Vulnerability Lists, which flag vulnerable individuals within a provider’s patient population, and the Inpatient Triage Assessment, which assesses whether admitted patients are at risk for needing a ventilator or mortality if infected with COVID-19. CareATC was among the first providers to use the Lists, proactively reaching out to vulnerable individuals in their patient population and advising them on how to navigate their risk.
- As lockdowns ended, Jvion launched the Employer Recovery Package, which includes an AI-enabled vulnerability assessment that evaluates employee’s risk of having severe outcomes if infected, enabling employers and employees to make more informed back-to-work decisions. The assessment was developed in collaboration with Augusta University Health System, who used the tool to safely bring back staff to resume elective procedures. It was also extended to employers in the greater Augusta community.
- Jvion also launched a new AI solution suite for payers that identifies members at high risk or on the cusp of becoming high risk for medication non-adherence, avoidable utilization and costs, or health deterioration, amongst other events. The solutions also provide member engagement and intervention recommendations specific to each member. The payer solutions have already been adopted by one national payer with over 13 million U.S. members.
“We learned a lot from the H1N1 pandemic, where clinical and socioeconomic risk factors drove a wide disparity in outcomes,” said Jvion Chief Product Officer Dr. John Showalter, MD, who was recently recognized by Modern Healthcare as one of the Top 25 Innovators of 2020 for his leadership in developing the COVID Community Vulnerability Map. “It’s been an exciting and humbling experience to refocus our clinical AI to protect vulnerable populations from COVID-19 and provide the insights our provider and payer customers need to navigate the financial and care management challenges of the pandemic.”
Jvion’s innovation in 2020 has been recognized by the industry. Frost & Sullivan gave Jvion the 2020 North American Technology Innovation Leadership Award for the Prescriptive Analytics Industry, and IDC named Jvion an IDC Innovator for applying AI to patient engagement issues.
“Jvion’s prescriptive analytics solution is making personalized medicine a reality by introducing AI to provide patient-specific prioritizations and interventions that guarantee the best outcomes,” said Cecilia Van Cauwenberghe, Associate Fellow and Industry Principal at Frost & Sullivan TechVision. “Jvion’s success is based on a profound understanding of the real needs of their partners, which drives the implementation of interoperable, seamless solutions straightforwardly into the clinical workflow.”
2020 has also been marked by major changes to the Jvion brand. Jvion’s signature clinical AI, formerly known as the Jvion Machine, was rebranded as the Jvion CORE™, which stands for Care Optimization and Recommendation Enhancement. The change was made to reflect where Jvion’s prescriptive insights reside within its customers’ workflows, as well as to capture the AI’s core purpose of improving and optimizing care.
“With providers losing millions in revenue during the pandemic, adopting clinical AI is no longer a matter of innovation, it’s a matter of survival,” said Jvion CEO Jay Deady. “Applying the prescriptive insights of clinical AI will be critical to preventing avoidable utilization and the associated costs, especially after months of deferred care. Payers will also need to be proactive in managing the health of their members if they are to survive the impacts of deferred care. This is where our clinical AI can make a difference.”
Jvion, a leader in clinical artificial intelligence, enables providers, payers and other healthcare entities to identify and prevent avoidable patient harm, utilization and costs. An industry first, the Jvion CORE™ goes beyond predictive analytics and machine learning to identify patients on a trajectory to becoming high-risk. Jvion then determines the interventions that will more effectively reduce risk and enable clinical and operational action. The CORE accelerates time to value by leveraging established patient-level intelligence to drive engagement across healthcare organizations, populations, and individuals. To date, the Jvion CORE has been deployed across hundreds of clients and resulted in millions saved. For more information, visit http://www.jvion.com.
Jvion PR Contact: